Bunch T Jared, May Heidi T, Afshar Kia, Alharethi Rami, Day John D
Intermountain Medical Center Heart Institute, Intermountain Medical Center, 5169 Cottonwood St, Murray, UT 84017, USA; Intermountain Heart Rhythm Specialists, Eccles Outpatient Care Center, Suite 510, Intermountain Medical Center, 5169 Cottonwood St, Murray, UT 84017, USA; Department of Internal Medicine, Stanford University, 300 Pasteur Drive, Palo Alto, CA 94305, USA.
Intermountain Medical Center Heart Institute, Intermountain Medical Center, 5169 Cottonwood St, Murray, UT 84017, USA.
Cardiol Clin. 2019 May;37(2):177-183. doi: 10.1016/j.ccl.2019.01.011. Epub 2019 Feb 27.
Observational trials have shown that atrial fibrillation ablation favorably impacts long-term outcomes in systolic heart failure. These outcomes have been confirmed by randomized prospective trials highlighting the favorable impact of ablation on left ventricular function and remodeling, risk of heart failure hospitalization, and mortality. Ablation along with established heart failure medications is new and supported conceptually by the value of restoring sinus rhythm, avoiding long-term antiarrhythmic drugs, and minimizing drug-drug interactions. Observational data suggest a potential long-term benefit of beta-blockers with ablation that becomes augmented as follow-up is extended from 1 to 5 years.
观察性试验表明，心房颤动消融术对收缩性心力衰竭的长期预后有积极影响。这些结果已得到随机前瞻性试验的证实，这些试验强调了消融术对左心室功能和重塑、心力衰竭住院风险及死亡率的积极影响。消融术与既定的心力衰竭药物联合使用是一种新的方法，从恢复窦性心律、避免长期使用抗心律失常药物以及尽量减少药物相互作用的价值来看，在概念上是有依据的。观察性数据表明，β受体阻滞剂与消融术联合使用可能具有长期益处，随着随访时间从1年延长至5年，这种益处会增加。
